1. Home
  2. MCBS vs EVO Comparison

MCBS vs EVO Comparison

Compare MCBS & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MetroCity Bankshares Inc.

MCBS

MetroCity Bankshares Inc.

HOLD

Current Price

$28.23

Market Cap

816.1M

Sector

Finance

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$2.43

Market Cap

895.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCBS
EVO
Founded
2006
1993
Country
United States
Germany
Employees
N/A
4766
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
816.1M
895.8M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
MCBS
EVO
Price
$28.23
$2.43
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$32.00
$7.00
AVG Volume (30 Days)
92.4K
108.8K
Earning Date
04-17-2026
05-05-2026
Dividend Yield
3.51%
N/A
EPS Growth
4.76
N/A
EPS
2.64
N/A
Revenue
N/A
N/A
Revenue This Year
$36.78
N/A
Revenue Next Year
$4.83
$7.13
P/E Ratio
$10.79
N/A
Revenue Growth
N/A
N/A
52 Week Low
$24.24
$2.31
52 Week High
$31.00
$4.80

Technical Indicators

Market Signals
Indicator
MCBS
EVO
Relative Strength Index (RSI) 47.35 34.47
Support Level $26.87 $2.31
Resistance Level $29.08 $3.78
Average True Range (ATR) 0.70 0.08
MACD 0.01 0.01
Stochastic Oscillator 46.61 25.54

Price Performance

Historical Comparison
MCBS
EVO

About MCBS MetroCity Bankshares Inc.

MetroCity Bankshares Inc is a holding company of its subsidiary Metro City Bank. It provides commercial banking services such as consumer and commercial checking accounts, savings accounts, certificates of deposits, commercial and consumer loans, money transfers and a variety of other banking services. The banks generate revenue from interest income. Its customers include small business owners, professionals, consumers, and real estate developers.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: